Effectiveness of the WearME System for COPD Severity and Respiratory Function
NCT ID: NCT06751537
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
128 participants
OBSERVATIONAL
2025-05-29
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease
NCT02615795
Effectiveness of Home Automated Telemanagement in Chronic Obstructive Pulmonary Disorder
NCT00752531
A Wearable and a Self-management Application for Chronic Obstructive Pulmonary Disease (COPD) Patients at Home
NCT03857061
An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD Subjects
NCT03745547
Telehealth Monitoring in Chronic Obstructive Pulmonary Disease
NCT01522859
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The symptoms of COPD include dyspnea (shortness of breath), coughing and the production of sputum. Recent data shows that the 30-day readmission rate of COPD patients is approaching 23%, creating a huge burden on the health care system. Exacerbations can commonly be treated in the home if detected early, so early recognition of symptoms signaling an impending COPD exacerbation may reduce readmission and associated healthcare costs. The standard adjuncts used to assess lung function (e.g., spirometry, plethysmography, CT scan) require oversight by medical experts, are time consuming, and do not allow for continuous and remote patient monitoring of an acute exacerbation. Early recognition of deteriorating patient's lung function will enable timely intervention and help manage changes in COPD severity.
2\. EFFECTIVENESS STUDY OVERVIEW
In this study, the WearME-Basic functionality will be validated while using the same hardware needed for the WearME-Basic app. Since the hardware collects all data needed to supply either the Basic or Pro app, the investigators will also gain insights on both the Basic and Pro simultaneously during this study.
This study will assess the effectiveness of the WearME-Pro system in monitoring COPD patients by measuring the accuracy and reliability of the system for forced expiratory volume (FEV₁), forced vital capacity (FVC), respiratory rate, heart rate, I:E ratio, spinal range of motion (ROM), and activity levels. Up to 128 COPD participants will be recruited from the LASARRUS outpatient clinic, Johns Hopkins and TidalHealth hospitals, and stratified into four groups based on the GOLD standard for severity stratification. Participants will be asked to wear the WearME system during a data collection period of 145 minutes.
The primary outcome measure will be the Bland-Altman LOA between the FEV1/FVC measurements of WearME-Pro FEV1/FVC prediction (recorded within the WearME-Basic app but not displayed to users) and the gold standard devices. Secondary outcomes include the validation of the WearME-Basic system for FDA submission by evaluating its accuracy in measuring respiration rate, heart rate, I:E ratio, and ROM compared to gold standard reference devices, and correlation of I:E measured by the WearME device to FEV1/FVC measured by spirometry.
We will use standard medical devices as reference devices for comparison with the WearME systems outputs. The specific devices used for spirometry, capnography, heart rate monitoring, and range of motion measurement will be appropriate, FDA-cleared devices commonly used in clinical practice.
Details of the specific device models and their usage will be documented in the Manual of Procedures (MOP). The sponsor will provide all necessary reference devices to the study sites, including the spirometers, capnographs, and other equipment required for the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COPD Participants
Participants are wearing the WearME device and undergoing reference testing
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with COPD as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria \[5\] , with the following severity levels (confirmed via spirometry performed after consent):
* Mild: FEV1/FVC \< 0.7 and FEV1 ≥ 80%
* Moderate: FEV1/FVC \< 0.7 and 50% ≤ FEV1 \< 80%
* Severe: FEV1/FVC \< 0.7 and 30% ≤ FEV1 \< 50%
* Very Severe: FEV1/FVC \< 0.7 and FEV1 \< 30% or FEV1 \< 50%, plus chronic respiratory failure.
Note: Participants will be consented and enrolled based on prior diagnosis of COPD from medical records within the past year to confirm eligibility and stratify COPD severity levels. Spirometry will be performed during concurrent data collection with the WearME device for comparison. Screening failures are expected and will be recorded and managed appropriately.
* Current, former, or never smoker; any amount of time between quitting and study enrollment is allowed).
* Ability to understand and willingness to sign consent documents.
* Able to participate in study procedures as required.
Exclusion Criteria
* Currently receiving invasive mechanical ventilation.
21 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Johns Hopkins University
OTHER
Tidalhealth
UNKNOWN
Tidalhealth, Inc.
UNKNOWN
Johns Hopkins Bloomberg School of Public Health
OTHER
LASARRUS Clinic and Research Center
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins
Baltimore, Maryland, United States
TidalHealth
Salisbury, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Nicholson PJ. The updated ATS/ERS spirometry technical standards. Occup Med (Lond). 2020 May 27;70(3):146-148. doi: 10.1093/occmed/kqaa030. No abstract available.
Lokke A, Lange P, Lykkegaard J, Ibsen R, Andersson M, de Fine Licht S, Hilberg O. Economic Burden of COPD by Disease Severity - A Nationwide Cohort Study in Denmark. Int J Chron Obstruct Pulmon Dis. 2021 Mar 10;16:603-613. doi: 10.2147/COPD.S295388. eCollection 2021.
GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020 Jun;8(6):585-596. doi: 10.1016/S2213-2600(20)30105-3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LAS-01-WZ-023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.